SEC Comment Letter for Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Oct 11, 2016
Oncocyte Corp (OCX) (CIK 0001642380)
Date: Oct. 11, 2016 · CIK: 0001642380 · Accession: 0000000000-16-096528
AI Filing Summary & Sentiment
File numbers found in text: 333-213810
Letter
Mail Stop 4546 October 11, 2016 William Annett President and Chief Executive Officer OncoCyte Corporation 1010 Atlantic Avenue, Suite 102 Alameda, California 94501
Re: OncoCyte Corporation Registration Statement on Form S-1 Filed September 2 6, 2016 File No. 333-213810
Dear Mr. Annett :
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Gershon at (202) 551 -6598 or Mary Beth Breslin at (202) 551 - 3625 with a ny questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 October 11, 2016 William Annett President and Chief Executive Officer OncoCyte Corporation 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 Re: OncoCyte Corporation Registration Statement on Form S-1 Filed September 2 6, 2016 File No. 333-213810 Dear Mr. Annett : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Gershon at (202) 551 -6598 or Mary Beth Breslin at (202) 551 - 3625 with a ny questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Bruce Jenett , Esq.